اخبار و اعلانات

 آمار

تعداد نشریات282
تعداد نشریات سازمان80
تعداد شماره‌ها3,168
تعداد مقالات35,197
تعداد مشاهده مقاله50,943,462
تعداد دریافت فایل اصل مقاله90,948,627
Zaki, Leila, Vafae Eslahi, Aida, Foroutan, Masoud, Pirestani, Majid, Hatam-Nahavandi, Kareem, Karimipour-saryazdi, Amir, Ghaffari Cherati, Mohammad, Diaz, Daniel, Badri, Milad. (1404). Enhanced Vaccine Design Strategies for Toxoplasmosis: A Computational Analysis of Toxoplasma gondii Rhoptry Protein 13 (ROP13). سامانه مدیریت نشریات علمی, 80(5), 1301-1320. doi: 10.32598/ARI.80.5.3301
Leila Zaki; Aida Vafae Eslahi; Masoud Foroutan; Majid Pirestani; Kareem Hatam-Nahavandi; Amir Karimipour-saryazdi; Mohammad Ghaffari Cherati; Daniel Diaz; Milad Badri. "Enhanced Vaccine Design Strategies for Toxoplasmosis: A Computational Analysis of Toxoplasma gondii Rhoptry Protein 13 (ROP13)". سامانه مدیریت نشریات علمی, 80, 5, 1404, 1301-1320. doi: 10.32598/ARI.80.5.3301
Zaki, Leila, Vafae Eslahi, Aida, Foroutan, Masoud, Pirestani, Majid, Hatam-Nahavandi, Kareem, Karimipour-saryazdi, Amir, Ghaffari Cherati, Mohammad, Diaz, Daniel, Badri, Milad. (1404). 'Enhanced Vaccine Design Strategies for Toxoplasmosis: A Computational Analysis of Toxoplasma gondii Rhoptry Protein 13 (ROP13)', سامانه مدیریت نشریات علمی, 80(5), pp. 1301-1320. doi: 10.32598/ARI.80.5.3301
Zaki, Leila, Vafae Eslahi, Aida, Foroutan, Masoud, Pirestani, Majid, Hatam-Nahavandi, Kareem, Karimipour-saryazdi, Amir, Ghaffari Cherati, Mohammad, Diaz, Daniel, Badri, Milad. Enhanced Vaccine Design Strategies for Toxoplasmosis: A Computational Analysis of Toxoplasma gondii Rhoptry Protein 13 (ROP13). سامانه مدیریت نشریات علمی, 1404; 80(5): 1301-1320. doi: 10.32598/ARI.80.5.3301

Enhanced Vaccine Design Strategies for Toxoplasmosis: A Computational Analysis of Toxoplasma gondii Rhoptry Protein 13 (ROP13)

Archives of Razi Institute
مقاله 24، دوره 80، شماره 5، آذر و دی 2025، صفحه 1301-1320    اصل مقاله (5.39 M)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.32598/ARI.80.5.3301
نویسندگان
Leila Zaki1؛ Aida Vafae Eslahi1؛ Masoud Foroutan2، 3؛ Majid Pirestani4؛ Kareem Hatam-Nahavandi5؛ Amir Karimipour-saryazdi4؛ Mohammad Ghaffari Cherati1؛ Daniel Diaz6؛ Milad Badri* 1
1Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran
2Research Center for Environmental Contaminants (RCEC), Abadan University of Medical Sciences, Abadan, Iran.
3Department of Basic Medical Sciences, Faculty of Medicine, Abadan University of Medical Sciences, Abadan, Iran.
4Department of Parasitology and Entomology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
5Department of Parasitology and Mycology, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran
6Faculty of Sciences, National Autonomous University of Mexico, Mexico City, Mexico.
چکیده
Introduction: Toxoplasma gondii, an intracellular parasite, utilizes a variety of rhoptry proteins (ROPs) to facilitate invasion and interaction with host cells. Among these ROPs, rhoptry protein 13 (ROP13) stands out for its expression in both bradyzoite and tachyzoite forms of T. gondii and its ability to engage with various host cytoplasmic compartments.
Materials & Methods: In this bioinformatics study, we employed a range of tools to predict the fundamental characteristics of the ROP13 protein.
Results: Our analysis revealed that the ROP13 protein consists of 400 amino acid residues with an average molecular weight (MW) of 44,714.15 daltons. The grand average of hydropathicity (GRAVY) was determined to be -0.311, indicating the protein’s hydrophilic nature, while the aliphatic index scored 84.40, highlighting its hydrophobic character. Furthermore, we identified 43 post-translationally modified sites within the ROP13 sequence. When examining the secondary structure, the ROP13 protein was predicted to have a composition of 40% alpha helix, 9.25% extended strand, and 50.75% random coil using the GOR4 method, suggesting a diverse structural organization that may contribute to its functional versatility. Additionally, our analysis identified several potential B- and T-cell epitopes within the ROP13 sequence, indicating regions that could be targeted for immune responses. 
Conclusion: The bioinformatics analysis of ROP13 provides valuable insights into its structural, immunogenic, and antigenic properties, highlighting its potential as a target for vaccine development against toxoplasmosis. By leveraging the predicted characteristics of ROP13, researchers can explore various vaccine strategies to enhance host immunity and combat T. gondii infection effectively. Continued investigation into the molecular mechanisms underlying ROP13’s interactions with host cells will further elucidate its role in T. gondii pathogenesis and guide the development of innovative approaches to mitigate this prevalent parasitic disease.
کلیدواژه‌ها
In silico؛ Rhoptry protein 13؛ Toxoplasma gondii
عنوان مقاله [English]
استراتژی‌های طراحی واکسن پیشرفته برای توکسوپلاسموزیس: تجزیه و تحلیل محاسباتی پروتئین روپتری 13(ROP13) توکسوپلاسما گوندی
چکیده [English]
توکسوپلاسما گوندی (T. gondii) ، یک انگل درون سلولی میباشد که از انواع پروتئین های راوپتری (ROPs) برای تسهیل تهاجم و تعامل با سلول های میزبان استفاده می کند. در میان این ROPها، Rhoptry Protein 13 (ROP13) به دلیل بیان آن در هر دو شکل برادی زوئیت و تاکی زوئیت T. gondii و توانایی آن در درگیر شدن با محفظه های سیتوپلاسمی میزبان متفاوت است. در این مطالعه بیوانفورماتیک، ما از طیف وسیعی از ابزارها برای پیش‌بینی ویژگی‌های اساسی پروتئین ROP13 استفاده کردیم. تجزیه و تحلیل ما نشان داد که پروتئین ROP13 از 400 باقیمانده اسید آمینه با میانگین وزن مولکولی (MW) 44714.15 دالتون تشکیل شده است. میانگین کل هیدروپاتیک (GRAVY) 0.311- تعیین شد که نشان‌دهنده ماهیت آبدوست پروتئین است، در حالی که شاخص آلیفاتیک امتیاز 84.40 را به‌دست آورد که ویژگی‌های آبگریز آن را برجسته می‌کند. علاوه بر این، ما 43 سایت تغییر یافته پس از ترجمه را در توالی ROP13 شناسایی کردیم. هنگام بررسی ساختار ثانویه، پروتئین ROP13 دارای ترکیبی از 40٪ آلفا-مارپیچ، 9.25٪ رشته گسترده، و 50.75٪ چنبره تصادفی با استفاده از GOR4 پیش بینی شد. روش، پیشنهاد یک سازمان ساختاری متنوع است که ممکن است به تطبیق پذیری عملکردی آن کمک کند. علاوه بر این، تجزیه و تحلیل ما چندین اپی توپ بالقوه سلول B و T را در توالی ROP13 شناسایی کرد که نشان‌دهنده مناطقی است که می‌توانند برای پاسخ‌های ایمنی هدف قرار گیرند.
به طور کلی، تجزیه و تحلیل بیوانفورماتیک ROP13 بینش های ارزشمندی را در مورد خواص ساختاری، ایمنی زایی و آنتی ژنی آن ارائه می دهد و پتانسیل آن را به عنوان یک هدف برای توسعه واکسن در برابر توکسوپلاسموز برجسته می کند. با استفاده از ویژگی‌های پیش‌بینی‌شده ROP13، محققان می‌توانند استراتژی‌های مختلف واکسن را برای تقویت ایمنی میزبان و مبارزه موثر با عفونت T. gondii بررسی کنند. ادامه تحقیقات در مورد مکانیسم‌های مولکولی زیربنای تعاملات ROP13 با سلول‌های میزبان، نقش آن را در پاتوژنز توکسوپلاسموز بیشتر روشن می‌کند و توسعه رویکردهای نوآورانه برای کاهش این بیماری انگلی شایع را راهنمایی می‌کند.
کلیدواژه‌ها [English]
توکسوپلاسما گوندی، Rhoptry protein 13, شبیه سازی رایانه ای
سایر فایل های مرتبط با مقاله
مراجع

References

  1. Rostami A, Riahi SM, Gamble HR, Fakhri Y, Nourollahpour Shiadeh M, Danesh M, et al. Global prevalence of latent toxoplasmosis in pregnant women: A systematic review and meta-analysis. Clin Microbiol Infect. 2020; 26(6):673-83. [DOI:10.1016/j.cmi.2020.01.008] [PMID]
  2. Abbasali Z, Pirestani M, Dalimi A, Badri M, Fasihi-Ramandi M. Anti-parasitic activity of a chimeric peptide Cecropin A (2- 8)-Melittin (6- 9)(CM11) against tachyzoites of Toxoplasma gondii and the BALB/c mouse model of acute toxoplasmosis. Mol Biochem Parasitol. 2023; 255:111578. [DOI:10.1016/j.molbiopara.2023.111578] [PMID]
  3. Rojas-Barón L, Tana-Hernandez L, Nguele Ampama MH, Sanchéz R, Gärtner U, Wagenlehner FME,et al. Adverse impact of acute Toxoplasma gondii infection on human spermatozoa. FEBS J. 2025; 292(17):4720-36. [PMID]
  4. Sanchez SG, Besteiro S. The pathogenicity and virulence of Toxoplasma gondii. Virulence. 2021; 12(1):3095-114. [DOI:10.1080/21505594.2021.2012346] [PMID]
  5. Haghbin M, Maani S, Bagherzadeh MA, Bazmjoo A, Shakeri H, Taghipour A, et al. Latent Toxoplasmosis among Breast Cancer Patients in Jahrom, South of Iran. Int J Breast Cancer. 2023; 2023:4792260. [DOI:10.1155/2023/4792260] [PMID]
  6. Dubey JP. The history of Toxoplasma gondii the first 100 years. J Eukaryot Microbiol. 2008; 55(6):467-75. [DOI:10.1111/j.1550-7408.2008.00345.x] [PMID]
  7. Wang ZD, Liu HH, Ma ZX, Ma HY, Li ZY, Yang ZB, et al. Toxoplasma gondii infection in immunocompromised patients: A systematic review and meta-analysis. Front Microbiol. 2017; 8:389. [DOI:10.3389/fmicb.2017.00389] [PMID]
  8. Mose JM, Kagira JM, Kamau DM, Maina NW, Ngotho M, Karanja SM, et al. A review on the present advances on studies of toxoplasmosis in eastern Africa. Biomed Res Int. 2020; 2020:7135268. [DOI:10.1155/2020/7135268] [PMID]
  9. Dupont CD, Christian DA, Hunter CA. Immune response and immunopathology during toxoplasmosis. Semin Immunopathol. 2012; 34(6):793-813. [DOI:10.1007/s00281-012-0339-3] [PMID]
  10. Abdoli A, Olfatifar M, Eslahi AV, Moghadamizad Z, Samimi R, Habibi MA, et al. A systematic review and meta-analysis of protozoan parasite infections among patients with mental health disorders: An overlooked phenomenon. Gut Pathog. 2024;16(1):7. [DOI:10.1186/s13099-024-00602-2] [PMID]
  11. Gharavi MJ, Jalali S, Khademvatan S, Heydari S. Detection of IgM and IgG anti-Toxoplasma antibodies in renal transplant recipients using ELFA, ELISA and ISAGA methods: Comparison of pre-and post-transplantation status. Ann Trop Med Parasitol. 2011; 105(5):367-71. [DOI:10.1179/1364859411Y.0000000022] [PMID]
  12. Weiss LM, Dubey JP. Toxoplasmosis: A history of clinical observations. Int J Parasitol. 2009; 39(8):895-901. [DOI:10.1016/j.ijpara.2009.02.004] [PMID]
  13. Tenter AM. Toxoplasma gondii in animals used for human consumption. Mem Inst Oswaldo Cruz. 2009; 104(2):364-9.[DOI:10.1590/S0074-02762009000200033] [PMID]
  14. Hajj RE, Tawk L, Itani S, Hamie M, Ezzeddine J, El Sabban M, et al. Toxoplasmosis: Current and emerging parasite druggable targets. Microorganisms. 2021; 9(12):2531. [DOI:10.3390/microorganisms9122531] [PMID]
  15. Antczak M, Dzitko K, Dugoska H. Human toxoplasmosis Searching for novel chemotherapeutics. Biomed Pharmacother. 2016; 82:677-84. [DOI:10.1016/j.biopha.2016.05.041] [PMID]
  16. Pagheh AS, Sarvi S, Sharif M, Rezaei F, Ahmadpour E, Dodangeh S, et al. Toxoplasma gondii surface antigen 1 (SAG1) as a potential candidate to develop vaccine against toxoplasmosis: A systematic review. Comp Immunol Microbiol Infect Dis. 2020; 69:101414. [DOI:10.1016/j.cimid.2020.101414] [PMID]
  17. Zhang NZ, Chen J, Wang M, Petersen E, Zhu XQ. Vaccines against Toxoplasma gondii: New developments and perspectives. Expert Rev Vaccines. 2013; 12(11):1287-99. [DOI:10.1586/14760584.2013.844652] [PMID]
  18. Rezaei F, Sarvi S, Sharif M, Hejazi SH, Pagheh AS, Aghayan SA, et al. A systematic review of Toxoplasma gondii antigens to find the best vaccine candidates for immunization. Microb Pathog. 2019; 126:172-84. [DOI:10.1016/j.micpath.2018.11.003] [PMID]
  19. Kazi A, Chuah C, Majeed ABA, Leow CH, Lim BH, Leow CY. Current progress of immunoinformatics approach harnessed for cellular-and antibody-dependent vaccine design. Pathog Glob Health. 2018; 112(3):123-31. [DOI:10.1080/20477724.2018.1446773] [PMID]
  20. Dlugonska H. Toxoplasma rhoptries: Unique secretory organelles and source of promising vaccine proteins for immunoprevention of toxoplasmosis. J Biomed Biotechnol. 2008; 2008:632424. [DOI:10.1155/2008/632424] [PMID]
  21. Pagheh AS, Daryani A, Alizadeh P, Hassannia H, Rodrigues Oliveira SM, Kazemi T, et al. Protective effect of a DNA vaccine cocktail encoding ROP13 and GRA14 with Alum nano-adjuvant against Toxoplasma gondii infection in mice. Int J Biochem Cell Biol. 2021; 132:105920. [DOI:10.1016/j.biocel.2021.105920] [PMID]
  22. Turetzky JM, Chu DK, Hajagos BE, Bradley PJ. Processing and secretion of ROP13: A unique Toxoplasma effector protein. Int J Parasitol. 2010; 40(9):1037-44. [DOI:10.1016/j.ijpara.2010.02.014] [PMID]
  23. Wang PY, Yuan ZG, Petersen E, Li J, Zhang XX, Li XZ, et al. Protective efficacy of a Toxoplasma gondii rhoptry protein 13 plasmid DNA vaccine in mice. Clin Vaccine Immunol. 2012; 19(12):1916-20. [DOI:10.1128/CVI.00397-12] [PMID]
  24. Kang HJ, Lee SH, Kim MJ, Chu KB, Lee DH, Chopra M, et al. Influenza virus-like particles presenting both Toxoplasma gondii ROP4 and ROP13 Enhance Protection against T. gondii infection. Pharmaceutics. 2019; 11(7):342. [DOI:10.3390/pharmaceutics11070342] [PMID]
  25. Zhou J, Wang L, Zhou A, Lu G, Li Q, Wang Z, et al. Bioinformatics analysis and expression of a novel protein ROP48 in Toxoplasma gondii. Acta Parasitol. 2016; 61(2):319-28. [DOI:10.1515/ap-2016-0042] [PMID]
  26. Romano P, Giugno R, Pulvirenti A. Tools and collaborative environments for bioinformatics research. Brief Bioinform. 2011; 12(6):549-61. [DOI:10.1093/bib/bbr055] [PMID]
  27. National Center for Biotechnology Information (NCBI). amino acid sequence of ROP13. National Center for Biotechnology Information; 2025. [Link]
  28. The Expasy ProtParam tool. Vaud: SIB Swiss Institute of Bioinformatics; 2025. [Link]
  29. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, et al. Protein identification and analysis tools on the ExPASy server. In: Walker JM, editor. The Proteomics Protocols Handbook. Springer Protocols Handbooks. New Jersey: Humana Press. [DOI:10.1385/1-59259-890-0:571]
  30. No Auther. The online tools NetPhos 3.1 [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
  31. No Auther. CSS-Palm. [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
  32. TMHMM-2.0. Kongens Lyngby: Technical University of Denmark; 2025. [Link]
  33. PSORT II Prediction [Internet]. 1999 [Updated 24 November 1999]. Available from: [Link]
  34. The secondary structure of ROP13 was predicted using the Garnier-Osguthorpe-Robson (GOR) method through the online server. 2025.
  35. Garnier J, Gibrat JF, Robson B. GOR method for predicting protein secondary structure from amino acid sequence. Methods Enzymol. 1996; 266:540-53. [DOI:10.1016/S0076-6879(96)66034-0] [PMID]
  36. SWISS-MODEL. SWISSMODEL program [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
  37. Guex N, Peitsch MC, Schwede T. Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective. Electrophoresis. 2009; 30(S1):S162--73. [DOI:10.1002/elps.200900140] [PMID]
  38. UCLA-DOE LAB — SAVES v6.1. PROCHECK tool [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
  39. Foroutan M, Karimipour-Saryazdi A, Ghaffari AD, Majidiani H, Arzani Birgani A, Karimzadeh-Soureshjani E, et al. In Silico Analysis and Characterization of the Immunogenicity of Toxoplasma gondii Rhoptry Protein 18. Bioinform Biol Insights. 2025; 19:11779322251315924. [DOI:10.1177/11779322251315924] [PMID]
  40. Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR. J Biomol NMR. 1996; 8(4):477-86. [DOI:10.1007/BF00228148] [PMID]
  41. Computational Resources for Drug Discovery. ABCpred server. [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
  42. Saha S, Raghava GP. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins. 2006; 65(1):40-8. [DOI:10.1002/prot.21078] [PMID]
  43. Computational Resources for Drug Discovery. Bcepred tool. 2025.
  44. Saha S, Raghava GPS. BcePred: prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties. Paper presented at: International Conference on Artificial Immune Systems. September 13-16, 2004; Catania, Sicily, Italy. [Link]
  45. IEDB Analysis Resource. IEDB tool [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
  46. IEDB Analysis Resource. ElliPro [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
  47. Ponomarenko J, Bui HH, Li W, Fusseder N, Bourne PE, Sette A, et al. ElliPro: A new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics. 2008; 9:514. [PMID]
  48. The Immune Epitope Database (IEDB). Assess the half maximal inhibitory concentration (IC50) of peptides derived from ROP13 that exhibit af finity to both major histocompatibility complex (MHC) class I and class II molecules [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
  49. IEDB Analysis Resource. MHC-I Binding Predictions [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
  50. IEDB Analysis Resource. MHC class II [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
  51. Wang P, Sidney J, Dow C, Mothé B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol. 2008; 4(4):e1000048. [DOI:10.1371/journal.pcbi.1000048] [PMID]
  52. Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics. 2010; 11:568. [PMID]
  53. tools. CTLpred tool. [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
  54. Bhasin M, Raghava GP. Prediction of CTL epitopes using QM, SVM and ANN techniques. Vaccine. 2004; 22(23-24):3195-204. [DOI:10.1016/j.vaccine.2004.02.005] [PMID]
  55. Scratch Protein Predictor. ANTI‌GENpro [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
  56. Magnan CN, Zeller M, Kayala MA, Vigil A, Randall A, Felgner PL, et al. High-throughput prediction of protein antigenicity using protein microarray data. Bioinformatics. 2010; 26(23):2936-43. [DOI:10.1093/bioinformatics/btq551] [PMID]
  57. The Edward Jenner Institute for Vaccine Research. VaxiJen v. 2.0. [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
  58. Doytchinova IA, Flower DR. VaxiJen: A server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007; 8:4. [PMID]
  59. Allergenic profile of ROP13 was predicted using the AlgPred [Internet]. 2025 [Updated 26 November 2025].
  60. Saha S, Raghava GP. AlgPred: Prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res. 2006; 34(Web Server issue):W202-9. [PMID]
  61. Magnan CN, Randall A, Baldi P. SOLpro: Accurate sequence-based prediction of protein solubility. Bioinformatics. 2009; 25(17):2200-7. [DOI:1093/bioinformatics/btp386] [PMID]
  62. C-IMMSIM. C-ImmSim was employed to simulate the virtual immunological response triggered by TgROP13 [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
  63. Kur J, Holec-Gasior L, Hiszczyńska-Sawicka E. Current status of toxoplasmosis vaccine development. Expert Rev Vaccines. 2009; 8(6):791-808. [DOI:10.1586/erv.09.27] [PMID]
  64. Dodangeh S, Fasihi-Ramandi M, Daryani A, Valadan R, Sarvi S. In silico analysis and expression of a novel chimeric antigen as a vaccine candidate against Toxoplasma gondii. Microb Pathog. 2019; 132:275-81. [DOI:10.1016/j.micpath.2019.05.013] [PMID]
  65. Berzofsky JA. Immunogenicity and antigen structure. Fundam Immunol. 1993; 235–82. [Link]
  66. El Hajj H, Demey E, Poncet J, Lebrun M, Wu B, Galéotti N, et al. The ROP2 family of Toxoplasma gondii rhoptry proteins: proteomic and genomic characterization and molecular modeling. Proteomics. 2006; 6(21):5773-84. [DOI:10.1002/pmic.200600187]
  67. Walsh C. Posttranslational modification of proteins: Expanding nature’s inventory. York City: W. H. Freeman and Company; 2006. [Link]
  68. DTU Health Tech. Number of predicted TMHs. DTU Health Tech; 2025. [Link]
  69. Yada RY, Jackman RL, Nakai S. Secondary structure prediction and determination of proteins: A review. Int J Pept Protein Res. 1988; 31(1):98–108. [DOI:10.1111/j.1399-3011.1988.tb00011.x]
  70. Predicted secondary structure by the GOR IV online service. [Internet]. 2025 [Updated 26 November 2025]. Available from: [Link]
  71. Wang Y, Wang G, Cai J, Yin H. Review on the identification and role of Toxoplasma gondii antigenic epitopes. Parasitol Res. 2016; 115(2):459-68. [DOI:10.1007/s00436-015-4824-1] [PMID]
  72. Zaki L, Ghaffarifar F, Sharifi Z, Horton J, Sadraei J. Effect of Imiquimod on Tachyzoites of Toxoplasma gondii and Infected Macrophages in vitro and in BALB/c Mice. Front Cell Infect Microbiol. 2020; 10:387. [DOI:10.3389/fcimb.2020.00387] [PMID]
  73. Zaki L, Ghaffarifar F, Sharifi Z, Horton J, Sadraei J. Toxoplasma gondii: Preventive and therapeutic effects of morphine and evaluation of treatment parameters of tachyzoites and infected macrophages in vitro and in a murine model. EXCLI J. 2020; 19:514-27. [PMID]
  74. Sayles PC, Gibson GW, Johnson LL. B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii. Infect Immun. 2000; 68(3):1026-33. [DOI:10.1128/IAI.68.3.1026-1033.2000] [PMID]
  75. El-Kady IM. T-cell immunity in human chronic toxoplasmosis. J Egypt Soc Parasitol. 2011; 41(1):17-28. [PMID]
  76. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. In- terferon-gamma: The major mediator of resistance against Toxoplasma gondii. Science. 1988; 240(4851):516-8. [DOI:10.1126/science.3128869] [PMID]
آمار
تعداد مشاهده مقاله: 768
تعداد دریافت فایل اصل مقاله: 420


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب